Neuronetics Stock

Neuronetics Net Debt

The Net Debt of Neuronetics (STIM) as of Aug 4, 2026 is 31.45 M USD. In the previous year, Net Debt was 35.49 M USD — a change of -11.38% (lower).

Net Debt

31.45 MUSD

YoY

-11.38%

Last updated:

Net Debt of Neuronetics is 2026 31.45 M USD. Net Debt of Neuronetics was 2025 35.49 M USD. It decreases by -11.38% lower compared to the previous year.
Access this data via the Eulerpool API

Neuronetics Stock analysis

What does Neuronetics do? Neuronetics Inc is a globally leading company in the field of non-invasive neuromodulatory technology. It was founded in 2003 and is headquartered in Malvern, Pennsylvania. The company specializes in the development and production of transcranial magnetic stimulation devices that can be used in the treatment of psychiatric disorders, particularly severe depression. Neuronetics' business model is based on selling its patented technology, called NeuroStar Advanced Therapy, to medical facilities worldwide. The company works closely with leading psychiatrists and clinical neurophysiologists to ensure that their devices meet the highest quality standards and can provide the best possible help to patients. The company has achieved a number of significant milestones in recent years. For example, in 2008, it received the first FDA approval for its technology. Since then, Neuronetics has continuously developed and improved its technology and has also obtained approvals in Europe and other parts of the world. Neuronetics is divided into various divisions, including research and development, manufacturing, and sales. Each of these departments is focused on ensuring the highest quality standards and ensuring that the technology of NeuroStar Advanced Therapy meets the needs of patients and medical personnel. The technology of NeuroStar Advanced Therapy is based on transcranial magnetic stimulation (TMS), which uses gentle magnetic fields to stimulate the activity of certain brain regions. The stimulation can help restore the balance of neurotransmitters in the brain and thus alleviate depression. Treatment with NeuroStar Advanced Therapy has significant advantages over conventional antidepressant medications. In many cases, it leads to faster improvement of symptoms and does not cause any of the undesirable side effects that can occur with medication. Overall, Neuronetics has developed a revolutionary technology with NeuroStar Advanced Therapy that can help millions of people around the world overcome their depression. The company is proud to contribute to improving the quality of life for people and will continue to develop innovative solutions in the field of neuromodulatory technology in the future. Neuronetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuronetics stock

Net Debt of Neuronetics is 31.45 M USD in 2026.

Net Debt of Neuronetics changed from 35.49 M USD to 31.45 M USD, representing a -11.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Neuronetics since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Neuronetics historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Neuronetics

All Key Metrics — Neuronetics